Work

COMPANION-002: A Randomized Phase II/III Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-Line Therapy in Patients With Advanced Biliary Tract Cancer

Year: 2026
Type: article
Abstract: Purpose Patients with previously treated biliary tract cancer (BTC) have a short median overall survival (OS) and few treatment options. Tovecimig, a bispecific antibody to delta-like ligand-4 and vascular endothelial growth factor (VEGF)-A, was evaluated in combination with paclitaxel in COMPANION-002, a randomized phase II/III study in pretreated patients with advanced BTC. Patients and Methods Patients with advanced BTC with one prior systemic therapy were randomly assigned to paclitaxel (80 mg/m 2 ; once weekly on days 1, 8 and 15) with or without tovecimig (10 mg/kg; once every 2 weeks on days 1 and 15) in each 28-day cycle. The primary end point was RECIST v1.1-defined overall response rate (ORR) as assessed by blinded independent central review (BICR). Secondary end points included progression-free survival (PFS) and OS. Crossover from the paclitaxel control arm to tovecimig plus paclitaxel was permitted following BICR-confirmed progression. Results A total of 168 patients were randomly assigned 2:1 to tovecimig + paclitaxel (n = 111) or paclitaxel alone (n = 57). Tovecimig + paclitaxel significantly improved BICR-assessed ORR (18.0% v 5.3%; P = .0228) and PFS (4.7 v 2.6 months; hazard ratio [HR], 0.44; P < .0001). Among 31 patients (54%) who crossed over, postprogression PFS (time from crossover to subsequent second progression) exceeded initial PFS (PFS from random assignment to initial progression on paclitaxel; 3.5 v 1.9 months; HR, 0.40; P = .0035). Overall, 142 patients (85%) received tovecimig; no difference in OS was observed (HR, 1.05; P = .779). The most common treatment-emergent adverse events (TEAEs) with tovecimig + paclitaxel were hypertension (69.4%) and fatigue (66.7%). Grade ≥3 TEAEs occurred in 93.5% and 64.2% of patients treated with tovecimig + paclitaxel and paclitaxel alone, respectively. Conclusion Tovecimig combined with paclitaxel significantly improved ORR and PFS versus paclitaxel alone as second-line therapy for patients with BTC.
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7223440479
FWCI:
Cites: 40
Cited by:
Related to: 10